GREAT POINT PARTNERS LLC

Registered adviser

CIK

1281446

Location

Greenwich, CT

Portfolio Value

Small $529,119,388

Diversification

Diversified

Reports for

JAY JEFFREY R Nordahl Lillian

Filing Date

Global Rank

#3,711 / 8,825 ▲ 162

Top Industry

Biotechnology 94.9%

Period ended 4 months ago

Filed Aug 14, 2026 · 3mo

26 quarters · since Mar 2020

Regulatory profile

From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.

Holder type

Registered adviser

Form ADV roster, Nov 1, 2026

Form ADV adviser

CRD 158423

Roster of Nov 1, 2026

Regulatory AUM

$1,777,101,406

Main clients

Pooled investment vehicles (100% of AUM)

Private funds

17 funds · Private equity funds

Focus by fund count, roster of Nov 1, 2026

$1,777,101,406 gross assets

Private funds on Schedule D 7.B.(1)

As filed Oct 14, 2024; SEC's bulk Form ADV archive ends with 2024 filings.

$1,926,429,780 gross assets in 20 funds Private equity funds $1,075,089,782 (18) Hedge funds $851,339,998 (2)

Form ADV history

Monthly rosters from Dec 2019; each row is a run with the same figures, newest first.

Rosters	Regulatory AUM	Main clients
Apr 2026 to Nov 2026	$1,777,101,406	Pooled investment vehicles (100%)
Apr 2025 to Mar 2026	$1,459,223,157	Pooled investment vehicles (100%)
May 2024 to Mar 2025	$1,988,112,264	Pooled investment vehicles (97%)
Apr 2024	$1,988,112,264	Pooled investment vehicles (97%)
May 2023 to Mar 2024	$1,918,004,856	Pooled investment vehicles (98%)
Apr 2023	$1,918,004,856	Pooled investment vehicles (98%)

4 earlier changes not shown.

Schedule 13D/13G stakes

Stakes of 5% or more disclosed on Schedule 13D or 13G, each on the filer's latest filing for the security. These are event-dated stakes, not the quarter-end 13F portfolio below.

Company	Schedule	Event date	Filed	Shares	% of class	Change	Status
RACC Research Alliance Corp III	13G	Sep 4, 2026	54d	504,891	6.49%	—	Current
JTTT JATT III Acquisition Corp	13G	Aug 26, 2026	2mo	450,000	5.83%	—	Current
AMAN Amanat Acquisition Corp.	13G/A	Jun 30, 2026	3mo	500,000	6.67%	0 since May 19, 2026	Current
JATT JATT II Acquisition Corp.	13G/A	Jun 30, 2026	3mo	500,000	6.23%	0 since Apr 17, 2026	Current
PMN ProMIS Neurosciences Inc.	13G/A	Jun 30, 2026	3mo	736,881	7.66%	-217,201 since Mar 31, 2026	Current
SCYX Scynexis Inc	13G/A	Jun 30, 2026	3mo	4,076,068	9.99%	+3,078,729 since Mar 31, 2026	Current
SLGL Sol-Gel Technologies Ltd.	13G	Mar 24, 2026	7mo	274,363	8.45%	—	Current

A 13D or 13G stays in force until its filer amends it and no amendment is due without a material change, so a stake with no filing in 24 months reads unconfirmed, never sold. An amendment reporting under 5% ends the filer's duty to amend, not necessarily the holding. Shares are restated onto today's split basis. Show 14 exited, below-5% or retired stakes

Portfolio style

Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.

Style

Diversified active

Top 10 weight 53.6%, 24.8 effective positions, active share 99.0% against the Russell 2000 as of 2026-06-30; it meets none of the index-like, systematic-like or concentrated tests

Turnover

High turnover

132.1% over the last four quarters (100%+)

Horizon

Short horizon

Value-weighted holding period 3.2 quarters (under 4)

Closest benchmark: the Russell 2000 as of 2026-06-30, active share 99.0%; sector active share 88.4% against the combined 13F book's sector weights.

Over time 26 measured quarters

How the bands are measured

Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.

Clone Performance

Build a hypothetical price-return history from this filer's public 13F holdings.

View clone backtest

Portfolio Concentration

41 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026

Top Position

15.2%

+8.0 pts

Top 5

35.7%

+4.6 pts

Top 10

55.4%

+2.9 pts

HHI

504

Diversified+121

Portfolio Trend

26 quarters · across all stocks

Sector Breakdown

As of Jun 30, 2026

Sector	% Portfolio	Value	Positions
Healthcare	98.0%	$518,359,388	39
Financial Services	2.0%	$10,760,000	2

Last Quarter's Activity

Export CSV

Jun 30, 2026 vs Mar 31, 2026

Added To

Positions the filer increased

7 positions

Ticker	Company	Δ Shares	Shares	Value
IRD	Opus Genetics, Inc.	+1,645,847	1,970,187	$8,097,468
ANNX	Annexon, Inc.	+1,000,000	3,500,000	$19,985,000
IMMX	Immix Biopharma, Inc.	+927,642	1,277,642	$13,172,489
VERA	Vera Therapeutics, Inc.	+401,488	600,836	$25,781,872
MLTX	MoonLake Immunotherapeutics	+355,813	855,813	$16,662,679
CTNM	Contineum Therapeutics, Inc.	+121,283	921,481	$15,103,073
LBRX	Lb Pharmaceuticals Inc	+17,221	317,221	$10,295,407
No positions match the current search.

Trimmed

Positions the filer reduced

10 positions

Ticker	Company	Δ Shares	Shares	Value
SCYX	Scynexis Inc	−6,610,055	944,292	$3,843,268
PALI	Palisade Bio, Inc.	−1,120,938	2,284,819	$4,775,271
AMLX	Amylyx Pharmaceuticals, Inc.	−1,050,000	700,000	$12,572,000
SLN	Silence Therapeutics plc	−570,489	450,000	$4,941,000
CLYM	Climb Bio, Inc.	−334,130	1,000,000	$13,040,000
PMN	ProMIS Neurosciences Inc.	−285,252	86,150	$1,133,734
NGNE	Neurogene Inc.	−147,820	352,180	$11,076,061
NKTR	Nektar Therapeutics	−141,453	175,000	$12,216,750
DRUG	Bright Minds Biosciences Inc.	−110,397	109,603	$7,694,130
VOR	Vor Biopharma Inc.	−50,000	1,700,000	$31,297,000
No positions match the current search.

New Positions

Positions the filer opened this quarter

10 positions

Ticker	Company	Shares	Value
ABVX	Abivax S.A.	204,314	$27,226,883
DFTX	Definium Therapeutics, Inc.	425,000	$19,992,000
SGMT	Sagimet Biosciences Inc.	2,029,933	$15,691,382
IFRX	InflaRx N.V.	3,046,557	$6,824,287
JATT	JATT II Acquisition Corp.	500,000	$5,680,000
ALT	Altimmune, Inc.	1,741,232	$5,293,345
AMAN	Amanat Acquisition Corp.	500,000	$5,080,000
ELVN	Enliven Therapeutics, Inc.	70,000	$3,552,500
RNTX	Rein Therapeutics, Inc.	2,575,000	$2,678,000
DBVT	DBV Technologies S.A.	156,906	$2,573,258
No positions match the current search.

Sold Out

Positions the filer fully exited

12 positions

Ticker	Company	Shares	Value
—		374,000	$31,479,580
—		675,000	$13,587,750
IMVT	Immunovant, Inc.	545,625	$13,553,325
JBIO	Jade Biosciences, Inc.	964,462	$13,550,691
ZBIO	Zenas BioPharma, Inc.	524,066	$10,245,490
CMPX	Compass Therapeutics, Inc.	1,350,000	$7,141,500
CNTX	Context Therapeutics Inc.	2,238,496	$5,864,859
UNCY	Unicycive Therapeutics, Inc.	796,558	$5,241,351
TENX	Tenax Therapeutics, Inc.	327,307	$5,233,638
PHVS	Pharvaris N.V.	82,800	$2,339,100
AVTX	Avalo Therapeutics, Inc.	124,666	$1,861,263
ALKS	Alkermes plc.	50,000	$1,768,000
No positions match the current search.

Portfolio Positions

Compact Export CSV View 13F filing

41 tracked positions · $529,119,388 total · filing declares 42 positions · $529,120,900 · as of Jun 30, 2026

All sectors Financial Services Healthcare

Ticker	Company	Type	Shares	Δ Shares	Value (USD)	% Δ Value	Held (qtrs)	Est. cost/share	% of Portfolio
ABVX	Abivax S.A. CALL + SHARES Healthcare	NEW	604,314	NEW	$80,530,883	NEW	1	$113.18	15.22%
VOR	Vor Biopharma Inc. Healthcare	Reduced	1,700,000	-50,000	$31,297,000	+0.2%	3	$17.64	5.91%
IBRX	ImmunityBio, Inc. PUT Healthcare	Held	3,000,800	0	$26,272,004	+14.1%	—	—	4.97%
VERA	Vera Therapeutics, Inc. Healthcare	Added	600,836	+401,488	$25,781,872	+221.5%	2	$39.19	4.87%
ZURA	Zura Bio Ltd Healthcare	Held	4,215,930	0	$24,873,987	−0.8%	13	$5.68	4.70%
ALMS	Alumis Inc. Healthcare	Held	856,061	0	$24,089,556	+27.7%	2	$25.00	4.55%
SLGL	Sol-Gel Technologies Ltd. Healthcare	Held	274,363	0	$20,341,272	−6.4%	2	$72.20	3.84%
RARE	Ultragenyx Pharmaceutical Inc. PUT Healthcare	NEW	600,000	NEW	$20,034,000	NEW	—	—	3.79%
DFTX	Definium Therapeutics, Inc. Healthcare	NEW	425,000	NEW	$19,992,000	NEW	1	$24.71	3.78%
ANNX	Annexon, Inc. Healthcare	Added	3,500,000	+1,000,000	$19,985,000	+44.3%	2	$5.60	3.78%
ORKA	Oruka Therapeutics, Inc. Healthcare	Held	183,330	0	$17,447,516	+94.0%	4	$14.82	3.30%
MLTX	MoonLake Immunotherapeutics Healthcare	Added	855,813	+355,813	$16,662,679	+78.8%	2	$17.21	3.15%
SGMT	Sagimet Biosciences Inc. Healthcare	NEW	2,029,933	NEW	$15,691,382	NEW	1	$6.80	2.97%
CTNM	Contineum Therapeutics, Inc. Healthcare	Added	921,481	+121,283	$15,103,073	+44.5%	3	$11.63	2.85%
IMMX	Immix Biopharma, Inc. Healthcare	Added	1,277,642	+927,642	$13,172,489	+313.1%	2	$8.75	2.49%
CLYM	Climb Bio, Inc. Healthcare	Reduced	1,000,000	-334,130	$13,040,000	+42.7%	3	$3.30	2.46%
AMLX	Amylyx Pharmaceuticals, Inc. Healthcare	Reduced	700,000	-1,050,000	$12,572,000	−48.3%	6	$3.96	2.38%
NKTR	Nektar Therapeutics Healthcare	Reduced	175,000	-141,453	$12,216,750	−46.3%	4	$41.06	2.31%
NGNE	Neurogene Inc. Healthcare	Reduced	352,180	-147,820	$11,076,061	+9.9%	11	unpriced	2.09%
LBRX	Lb Pharmaceuticals Inc Healthcare	Added	317,221	+17,221	$10,295,407	+39.2%	2	$23.41	1.95%
IRD	Opus Genetics, Inc. Healthcare	Added	1,970,187	+1,645,847	$8,097,468	+448.7%	2	$4.47	1.53%
EPRX	Eupraxia Pharmaceuticals Inc. Healthcare	Held	1,200,000	0	$7,932,000	−8.7%	4	$5.44	1.50%
DRUG	Bright Minds Biosciences Inc. Healthcare	Reduced	109,603	-110,397	$7,694,130	−52.1%	2	$80.49	1.45%
IFRX	InflaRx N.V. Healthcare	NEW	3,046,557	NEW	$6,824,287	NEW	1	$1.88	1.29%
RLMD	Relmada Therapeutics, Inc. Healthcare	Held	842,106	0	$5,827,373	−0.6%	2	$4.73	1.10%
JATT	JATT II Acquisition Corp. Financial Services	NEW	500,000	NEW	$5,680,000	NEW	1	$10.63	1.07%
CGEM	Cullinan Therapeutics, Inc. Healthcare	Held	300,000	0	$5,463,000	+28.1%	3	$9.02	1.03%
ALT	Altimmune, Inc. Healthcare	NEW	1,741,232	NEW	$5,293,345	NEW	1	$2.99	1.00%
AMAN	Amanat Acquisition Corp. Financial Services	NEW	500,000	NEW	$5,080,000	NEW	1	$10.10	0.96%
RZLT	Rezolute, Inc. Healthcare	Held	951,809	0	$4,949,406	+70.5%	7	$4.03	0.94%
SLN	Silence Therapeutics plc Healthcare	Reduced	450,000	-570,489	$4,941,000	−8.1%	3	$6.22	0.93%
PALI	Palisade Bio, Inc. Healthcare	Reduced	2,284,819	-1,120,938	$4,775,271	−19.9%	2	$1.82	0.90%
EVMN	Evommune, Inc. Healthcare	Held	325,000	0	$4,319,250	−42.2%	3	$18.78	0.82%
SCYX	Scynexis Inc Healthcare	Reduced	944,292	-6,610,055	$3,843,268	−44.5%	2	$6.18	0.73%
GALT	Galectin Therapeutics Inc CALL Healthcare	Held	800,000	0	$3,712,000	+66.3%	—	—	0.70%
ELVN	Enliven Therapeutics, Inc. Healthcare	NEW	70,000	NEW	$3,552,500	NEW	1	$42.45	0.67%
HUMA	Humacyte, Inc. Healthcare	Held	3,750,000	0	$2,925,000	+28.5%	2	$1.04	0.55%
RNTX	Rein Therapeutics, Inc. Healthcare	NEW	2,575,000	NEW	$2,678,000	NEW	1	$1.21	0.51%
DBVT	DBV Technologies S.A. Healthcare	NEW	156,906	NEW	$2,573,258	NEW	1	$18.87	0.49%
AVXL	Anavex Life Sciences Corp. CALL Healthcare	Held	521,300	0	$1,350,167	−15.6%	—	—	0.26%
PMN	ProMIS Neurosciences Inc. Healthcare	Reduced	86,150	-285,252	$1,133,734	−76.0%	2	$14.91	0.21%

Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.